Literature DB >> 11544314

Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction.

T Nisihara1, Y Ushio, H Higuchi, N Kayagaki, N Yamaguchi, K Soejima, S Matsuo, H Maeda, Y Eda, K Okumura, H Yagita.   

Abstract

Fas ligand (L)/CD95L, a proapoptotic member of the TNF family, is a potential target for clinical intervention in various diseases. In the present study, we generated a humanized anti-human FasL mAb and characterized the epitopes of neutralizing mAbs by extensive alanine-scanning mutagenesis of human FasL. The predicted molecular model of FasL trimer revealed that the mAbs recognize largely overlapped conformational epitopes that are composed of two clusters, one around the outer tip-forming D-E loop and another near the top of FasL. Both of these sites on FasL are critically involved in the direct interaction with the corresponding receptor, Fas. These results suggest that the mAbs efficiently neutralize FasL cytotoxicity by masking both of these FasL/Fas contact sites.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11544314     DOI: 10.4049/jimmunol.167.6.3266

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  The human immunodeficiency virus type 1 tat protein enhances Cryptosporidium parvum-induced apoptosis in cholangiocytes via a Fas ligand-dependent mechanism.

Authors:  Steven P O'Hara; Aaron J Small; Jeremy B Nelson; Andrew D Badley; Xian-Ming Chen; Gregory J Gores; Nicholas F Larusso
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

2.  Precise structural determination of weakly binding peptides by utilizing dihedral angle constraints.

Authors:  Yumiko Mizukoshi; Michiko Nagasu; Ichio Shimada; Hideo Takahashi
Journal:  J Biomol NMR       Date:  2010-03-14       Impact factor: 2.835

3.  Natural killer cells induce distinct modes of cancer cell death: Discrimination, quantification, and modulation of apoptosis, necrosis, and mixed forms.

Authors:  Christian S Backes; Kim S Friedmann; Sebastian Mang; Arne Knörck; Markus Hoth; Carsten Kummerow
Journal:  J Biol Chem       Date:  2018-09-06       Impact factor: 5.157

4.  Rapid preparation of stable isotope labeled peptides that bind to target proteins by a phage library system.

Authors:  Yumiko Mizukoshi; Hideo Takahashi; Ichio Shimada
Journal:  J Biomol NMR       Date:  2006-01       Impact factor: 2.835

5.  Fas receptor-deficient lpr mice are protected against acetaminophen hepatotoxicity due to higher glutathione synthesis and enhanced detoxification of oxidant stress.

Authors:  C David Williams; Mitchell R McGill; Anwar Farhood; Hartmut Jaeschke
Journal:  Food Chem Toxicol       Date:  2013-04-27       Impact factor: 6.023

6.  Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus.

Authors:  Bhawna Poonia; Maria S Salvato; Hideo Yagita; Toshihiro Maeda; Ko Okumura; C David Pauza
Journal:  Blood       Date:  2009-06-04       Impact factor: 22.113

7.  Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  Sarah Nikiforow; Kim Bottomly; George Miller; Christian Münz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 8.  Role of the Fas/FasL pathway in HIV or SIV disease.

Authors:  Bhawna Poonia; C David Pauza; Maria S Salvato
Journal:  Retrovirology       Date:  2009-10-15       Impact factor: 4.602

9.  Attenuated disease in SIV-infected macaques treated with a monoclonal antibody against FasL.

Authors:  Maria S Salvato; C Cameron Yin; Hideo Yagita; Toshihiro Maeda; Ko Okumura; Ilia Tikhonov; C David Pauza
Journal:  Clin Dev Immunol       Date:  2007

10.  Expansion of FasL-Expressing CD5+ B Cells in Type 1 Diabetes Patients.

Authors:  Ankit Saxena; Hideo Yagita; Thomas W Donner; Abdel Rahim A Hamad
Journal:  Front Immunol       Date:  2017-04-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.